Oncotelic Therapeutics (OTLC)
OTHER OTC:OTLC
US Market
Holding OTLC?
Track your performance easily

Oncotelic Therapeutics (OTLC) Income Statement

79 Followers

Oncotelic Therapeutics Income Statement

Last quarter (Q2 2024), Oncotelic Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Oncotelic Therapeutics's net income was $-209.84K. See Oncotelic Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 70.00K$ 70.00K--$ 1.74M-
Cost of Revenue
------
Gross Profit
$ 70.00K$ 70.00K--$ 1.74M-
Operating Expense
$ 61.35K$ 6.72M$ 9.72M$ 9.13M$ 9.33M$ 4.31M
Operating Income
$ -325.80K$ -6.65M$ -9.72M$ -9.13M$ -7.58M$ -4.31M
Net Non Operating Interest Income Expense
$ -843.44K$ -1.04M$ -2.97M$ -2.00M$ -2.00M$ -749.48K
Other Income Expense
$ -6.86M$ -6.60M$ 13.26M$ -611.41K$ 388.75K$ 1.77M
Pretax Income
$ -1.10M$ -8.21M$ 4.68M$ -10.52M$ -9.97M$ -6.64M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -1.24M$ -7.90M$ 5.09M$ -9.39M$ -9.50M$ -13.28M
Basic EPS
-$ -0.02$ 0.01$ -0.03$ -0.11-
Diluted EPS
-$ -0.02$ 0.01$ -0.03$ -0.11$ -0.11
Basic Average Shares
$ 1.60B$ 396.17M$ 384.08M$ 303.08M$ 88.10M$ 59.96M
Diluted Average Shares
$ 1.60B$ 396.17M$ 457.30M-$ 88.10M$ 59.96M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 61.35K$ 634.87K$ 5.61M$ 9.13M$ 9.33M$ 4.31M
Net Income From Continuing And Discontinued Operation
$ -1.24M$ -7.90M$ 5.09M$ -9.39M$ -9.50M$ -13.28M
Normalized Income
$ -901.82K$ -476.72K-$ -8.31M--
Interest Expense
------
EBIT
$ -420.66K$ -7.16M$ 7.65M$ -8.51M$ -7.97M$ -6.69M
EBITDA
$ -16.39K$ -7.16M$ 7.66M$ -8.45M$ -7.61M$ -5.88M
Currency in USD

Oncotelic Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis